Letter sent in response to the press release issued by Sangamo BioSciences on January 9th 2012, the undersigned individuals and organizations are writing to express concern about the status of the SB-728-T development program.
ACTG Investigators Scramble to Convince Industry They Can Produce Searle Study Could Usher in New Era of Efficeincy at ACTG -- or Drive Final Nail in Coffin Like a slap-stick comedy sketch from a kiddy's cartoon escapade, the AIDS Clinical…
ICC's Brainchild Designed to Show Every Drug and Every Combination a Success. Who Could Complain About That? "It's ddC Monotherapy All Over Again" A hastily organized meeting of the newly formed Inter-Company Collaborative (ICC) was convened April 26 at the…
Accelerated Approval Guidelines Expedite Bristol's Launch of New Nucleoside -- In the Absence of Any Proof That It Works Specter of Fast Track Review Haunts Those Who Spawned It "FDA Panel Recommends Drug Despite Incomplete Data." So read the New…
KS Proves Formidable Foe As Angiogenesis Inhibitors and Stealth Chemotherapy Fall Short of Expectations Pregnant Mice the Key? Michael Marco recently returned from a transcontinental tour of KS research laboratories. While his official report is not due out for another…
One Company's Search for an Effective Antiviral Contrasts Another's Scramble for the Easy Money The Perils & Pains of Integrity Early on a rainy Monday morning, Merck scientists Emilio Emini and John Ryan assembled overheads and flip charts before a…
Study After Study, Antiretroviral Analyses Confound More Than They Clarify Lamenting the Naked Emperor First there was Concorde, the now notorious Anglo-French study which last summer sent shock waves across the Atlantic as it cast doubt on the wisdom of…
TAG and other partner organizations issued this letter about their serious and unresolved concerns about the proposed clinical trial comparing stavudine at 20 mg to tenofovir.
TAG’s annual review of progress we’ve made on the the fight to end HIV/AIDS, Viral Hepatitis, and Tuberculosis.